We spoke to Professor Hugh Calkins (Nicholas J. Fortuin M.D. Professor of Cardiology, Director, Electrophysiology Laboratory and Arrhythmia Service, Johns Hopkins Hospital, Baltimore, MD, USA) at Heart Rhythm 2019 about upcoming developments in atrial fibrillation (AF) ablation and his thoughts on the use or the discontinuation of anticoagulants in patients without recurrence after AF ablation.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Hugh Calkins is a consultant for and has received honoraria from Biosense Webster, Medtronic, Abbott, Boston Scientific and Boehringer Ingelheim.
1. What developments should we expect to see in atrial fibrillation (AF) ablation over the next few years? (0:09)
2. What are your thoughts on the use versus the discontinuation of anticoagulants in patients without recurrence of disease after AF ablation? (0:53)
3. What are your key take-home messages from Heart Rhythm 2019? (2:02)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
Share this Video
Related Videos In Atrial Fibrillation
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Suneet Mittal, AF Symposium 2021: Atrial Fibrillation in the Post-COVID-19 Environment
We spoke to Dr Suneet Mittal (Director of Electrophysiology, The Valley Hospital, Ridgewood, NJ, USA) about the workflow innovations for atrial fibrillation ablation in the post-COVID-19 environment. Questions What have been the main challenges to atrial fibrillation (AF) ablation workflow during the COVID-19 pandemic? (0.14) What workflow innovations have been created and incorporated over the […]
Hugh Calkins, AF Symposium 2021: the STOP Persistent AF Clinical Trial
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about the STOP Persistent AF Clinical Trial (NCT03012841). Questions: Could you tell us a little about the aims and design of the STOP Persistent AF clinical trial? (0.13) What were the findings of the study? (0.43) What are their implications for clinical practice? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!